Sun Pharma, an Indian generic drugmaker, is acquiring Organon for $11.75 billion in its largest acquisition ever, financing the bulk through $8.6 billion in assumed debt despite ending 2025 with only $198 million in debt and $1.16 billion annual profit. The deal transforms Sun…
Sun Pharma, an Indian company that built its fortune making low-cost copies of off-patent drugs, has agreed to buy Organon for $11.75 billion per the Organon press release: its largest acquisition ever and a striking bet on branded medicine at a moment when generic profit margins are under pressure everywhere.
The all-cash deal values each Organon share at $14, a 24% premium over the company's closing price on April 24 per Reuters. Sun Pharma will finance the bulk of the purchase by assuming Organon's existing debt, $8.6 billion of it, against just $574 million in cash on hand, while putting up roughly $3.2 billion in cash of its own per the Organon press release. The transaction is expected to close in early 2027, pending regulatory and stockholder approval.
For Sun Pharma, the numbers tell a story of deliberate reinvention. The company ended 2025 with nearly no debt, just $198 million, against annual profit of $1.16 billion per Reuters. In one move, it is loading $8.6 billion of borrowed money onto its balance sheet. That is a significant U-turn for a business that has historically grown through acquisitions while preserving a fortress balance sheet.
The prize is Organon itself: a company that Merck spun off in 2021, calling it non-core to Merck's strategy. Organon sells more than 70 products across women's health and general medicines in 140 countries, generated $6.2 billion in revenue last year, and employs roughly 10,000 people per the Organon press release. Its portfolio includes birth control implants, fertility treatments, and a biosimilars business that makes cheaper versions of biologic drugs, which are expensive to manufacture because they are grown from living cells rather than synthesized chemically.
Biosimilars are one of the faster-growing segments in global pharma. A biologic drug that loses patent protection can be copied by a biosimilar manufacturer at significantly lower cost, and those copies can compete on price in ways that traditional generic pills cannot. Sun Pharma is buying an established foothold in that market rather than building one from scratch.
The deal would move Sun Pharma's innovative medicine revenue from 20% of total sales to 27% overnight per CNBC, making it a top-three global player in women's health by revenue alongside Pfizer and Bayer. The combined company would generate $12.4 billion in annual revenue, placing it among the top 25 pharmaceutical companies worldwide per the Organon press release.
Sun Pharma has made five acquisitions in the past 16 years, including Taro Pharma in 2007 and Ranbaxy Laboratories in 2014 per CNBC. Both were rescue operations in different ways: Taro was a troubled Israeli generic company, and Ranbaxy was a scandal-scarred Indian rival that Sun Pharma acquired from Daiichi Sankyo after the deal went sideways. Organon is different. It is not distressed. It is profitable and growing in some segments, though it carries debt that is expensive to service. Organon's net debt-to-EBITDA ratio stands at 4 times; after the combination, the merged entity's ratio would fall to 2.3 times per CNBC, a level considered manageable for a company of that scale.
Not everyone is convinced the math works. "Deals like this tend to be strategically positive but financially nuanced," said Bhavesh Shah, managing director and head of investment banking at Equirus Capital. "Acquisitions can be value accretive over the medium to long term if they strengthen the company's portfolio or market reach and add scale, but in the near term, such deals can lead to higher leverage integration costs and execution risks." Salil Kallianpur, a pharma analyst, was more blunt: when a company pays a higher acquisition price, it significantly reduces its margin for error. "Value won't be acquired but created after you buy it," he said, noting that success depends on execution in a US market where pricing is controlled by payers and litigation risks remain significant. Unlike Sun Pharma's earlier rescue acquisitions, Organon is a stable platform, not a distressed asset: there is no turnaround to execute, only integration to get right.
The strategic logic Sun Pharma has offered is access: to US hospital and clinic networks that have been slow to adopt generic drugs from Indian manufacturers, to branded products that command real pricing power, and to a women's health portfolio that is genuinely difficult to replicate from scratch. What the company has not said publicly is the timeline for deleveraging, or what happens to Organon's product portfolio if generic competition intensifies faster than expected.
What this means for founders: Sun Pharma just became a better-funded, more formidable competitor in women's health and biosimilars than it was yesterday, and a potential acquirer rather than just a potential partner for startups in those spaces. The deal closes in early 2027, which gives Sun roughly three years to start integrating those 70 products into its global distribution network before the deal closes: a window during which the competitive positioning of every company in those categories is quietly in play.